Letrozol Almus (Letrozole)

Letrozol Almus acts on estrogen‑dependent breast cancer pathways and is used in several clinical settings.

• Postmenopausal hormone receptor‑positive breast cancer: reduces tumor growth by lowering estrogen levels.
• Adjuvant therapy for early‑stage breast cancer: decreases risk of recurrence after surgery.
• Metastatic breast cancer: helps control disease progression in estrogen‑dependent tumors.

• Letrozole selectively inhibits the aromatase enzyme, which converts adrenal and peripheral androgens into estrogens. By blocking this conversion, systemic estrogen concentrations fall, depriving estrogen‑dependent tumor cells of a growth stimulus and thereby slowing or halting tumor proliferation.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Hot flashes: sudden feeling of warmth, often with sweating.
• Joint and muscle pain: aching in joints or muscles.
• Fatigue: persistent tiredness not relieved by rest.
• Nausea: upset stomach, sometimes with vomiting.
• Headache: mild to moderate head pain.
• Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects

• Severe liver injury: jaundice, dark urine, abdominal pain.
• Bone fracture: increased risk due to reduced estrogen.
• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Cardiovascular events: hypertension or cardiac arrhythmia.
• Severe allergic reaction: rash, swelling, difficulty breathing.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor for potential complications.

• Monitor liver function: check hepatic enzymes periodically.
• Assess bone health: consider calcium and vitamin D supplementation and bone density testing.
• Contraindicated in pregnancy: category X, avoid exposure in women of childbearing potential.
• Review concomitant medications: evaluate for possible drug‑drug interactions.
• Educate on thromboembolic signs: advise patients to seek immediate care for leg swelling or chest pain.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Letrozole can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Tamoxifen: concurrent use may reduce the effectiveness of both agents.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower letrozole plasma concentrations.
• Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase letrozole exposure and risk of toxicity.

Moderate Interactions (Monitor Closely)

• Warfarin: letrozole may affect INR; monitor coagulation parameters.
• SSRIs (e.g., fluoxetine, paroxetine): potential alteration of metabolism; observe for side‑effects.
• Statins: monitor for changes in lipid levels and muscle symptoms.